ClinicalTrials.gg
TerminatedNCT00275262Updated May 6, 2010Results posted

A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

A Phase 2 interventional study of Leuprolide acetate depot (LAD) 11.25 mg 3 Month and Matched placebo in Hodgkin Disease, Lymphoma, Non-Hodgkin and Multiple Myeloma, sponsored by Abbott. Terminated at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-05-06.

Sponsored by Abbott · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 970 studies in Hodgkin Disease with a site in United States — 75 open to participants now, 142 under way, 6 of them phase 3. Hodgkin Disease · United States.

Enrollment
503rd of 818
25 · median 35
Started
2006
with 44 others
Phase 2
346 of 970
30 open now
Registered
266th of 970
by date

Among the 970 studies in Hodgkin Disease with a site in United States, this one is the 503rd largest by enrollment of the 818 interventional ones that give a count, is one of 45 that started in 2006, is one of 346 in phase 2, and was the 266th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

75 of the 970 studies in Hodgkin Disease with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 970 studies in Hodgkin Disease with a site in United States, or all of them as a file.
02

Study summary

Phase 2 study, conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.

Read the detailed description

This Phase 2 study will be conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation. Patients will be randomized to receive either LAD 11.25 mg 3 Month treatment or placebo and all patients will be vaccinated with KLH 6 months posttransplant. Patients will be evaluated to determine if the rate of immunologic recovery in the LAD group is enhanced compared with the placebo group.

03

Conditions studied

  • Hodgkin Disease
  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma
  • Mantle Cell Lymphoma

Keywords

  • Bone marrow transplantation
  • Hematopoietic stem cell transplantation
  • Hodgkin's disease
  • non-Hodgkin's lymphoma
  • multiple myeloma
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be female between the ages of 18 - 50 or if female > 50 years old have an estradiol concentration level >= 30 pg/mL and follicle stimulating hormone level \< 40 mIU/mL, or male between the ages of 18-65 (inclusive).
  2. Must have Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma and be considered an appropriate candidate for hematopoietic stem cell transplant.

    1. Multiple myeloma patients should have had a partial or complete response to chemotherapy.
    2. Patients with Hodgkin's disease or non-Hodgkin's lymphoma who achieve a partial response to initial chemotherapy or first or second chemosensitive relapse, achieving a complete or partial response to salvage treatment. Patients in first remission with mantle cell lymphoma, or with intermediate or high grade lymphoma, presenting with high intermediate or high IPI (International Prognostic Index) scores are also eligible.
  3. Must be seronegative for and .
  4. Must have received prior tetanus immunization
  5. Must not have received prior KLH immunization.
  6. Must have an performance status (PS) \<= 1 or PS >= 70%.
  7. Must have creatinine \<= 2.0 mg/dL; > 45%; carbon monoxide diffusion in the lungs (DLCO) > 50% of predicted; serum \< 1.5 times the unless Gilbert's syndrome, \< 3 times normal value.
  8. Must be more than 3 weeks from any prior surgery (except for central line placement) and have fully recovered from the effects of surgery.
  9. Must have an (ANC) >= 1,500 µL, count >= 100,000/µL and >= 8.0 gm/dL within 21 days prior to randomization.
  10. Must be able to return to the clinical site for follow-up visits.
  11. Must be able to provide written consent.

Exclusion criteria

Exclusion Criteria:

  1. Must not have an uncontrolled life-threatening infection (or active infectious process requiring intravenous [IV] systemic medical therapy within 1 week prior to study enrollment).
  2. Must not have a diagnosed or suspected schistosomiasis infection.
  3. Must not have previously received hematopoietic stem cell transplantation.
  4. Must not require a tandem transplant.
  5. Must not be female with a positive pregnancy test, pregnant, or lactating and breast feeding, or wish to become pregnant during the course of the study. Must agree to use barrier method of .
  6. Must not be receiving estrogen or testosterone replacement therapy,phytoestrogen, phyto-testosterone, or oral contraceptives (patients may enroll if oral contraceptives are ceased prior to study entry), or have been administered Depo Provera within 3 months of entering the study.
  7. Must not have had prior mediastinal or sternal radiation.
  8. Must not have received any drug other than antibiotics within 3 weeks prior to study drug administration or are scheduled to receive an investigational drug during the course of this study.
  9. Must not have unstable cardiac arrhythmias, uncontrolled congestive heart failure, history of myocardial infarction (MI) or ischemia, stroke, or embolic events within 6 months before study start.
  10. Must not have medical or psychiatric conditions that, in the opinion of the investigator, would compromise the patient's ability to participate in the study.
  11. Must not be receiving or plan to receive palifermin (KGF).
  12. Must not have a allergy to shellfish.
  13. Must not have previously taken a GnRH analog within 18 months.
  14. Must not be a woman who has undergone bilateral oophorectomy, or man with orchiectomy.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    LAD 11.25 mg 3 Month Depot

    Three intramuscular injections LAD 11.25 mg 3 Month treatment administered approximately 3 months apart.

    Drug: Leuprolide acetate depot (LAD) 11.25 mg 3 Month

  • Placebo comparator
    Placebo Comparator

    Three intramuscular injections of matched placebo administered approximately 3 months apart.

    Drug: Matched placebo

Interventions

  • LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.

    Also known as: Lupron

  • DrugMatched placebo

    Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in IgM Response (Mcg/mL) Before Keyhole Limpet Hemocyanin (KLH) Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo

    Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Serum immunoglobulin IgM antibodies were determined by enzyme-linked immunosorbent assay (ELISA). Baseline is defined as the IgM concentration before the KLH vaccination. Change from baseline was calculated as the IgM value postvaccination minus the IgM value at prevaccination.

    Time frame: Month 6 prevaccination (baseline) and Month 7 postvaccination

  2. Mean Change From Baseline in IgG1 Response (Mcg/mL) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo

    Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Serum immunoglobulin IgG1 antibodies were determined by enzyme-linked immunosorbent assay (ELISA). Baseline is defined as the IgG1 concentration before the KLH vaccination. Change from baseline was calculated as the IgG1 value postvaccination minus the IgG1 value at baseline.

    Time frame: Month 6 prevaccination (baseline) and Month 7 postvaccination

  3. Mean Change From Baseline in Interferon Gamma Response (Spots/1 Million Cells) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo

    Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Interferon gamma was determined by enzyme-linked immunosorbent spot-forming cell (ELISpot). Baseline is defined as the interferon gamma concentration obtained before the KLH vaccination. Change from baseline was calculated as the interferon gamma value postvaccination minus the interferon gamma value at baseline.

    Time frame: Month 6 prevaccination (baseline) and Month 7 postvaccination

Secondary outcomes

  1. Mean Change From Baseline in T Cell Excision Circles (TREC) Per 100,000 CD4+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant

    CD4+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD4 cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD4+ cells minus pretransplant TREC /100,000 CD4+ cells.

    Time frame: Pretransplant and posttransplant (Month 12)

  2. Mean Change From Baseline in TREC Per 100,000 CD8+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant

    CD8+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD8+ cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD8+ cells minus pretransplant TREC /100,000 CD8+ cells.

    Time frame: Pretransplant and posttransplant (Month 12)

07

Results

Posted May 6, 2010
Limitations and caveats
The study was terminated early because of slow enrollment. For the primary endpoint, changes from baseline within each treatment group were analyzed. Between treatment group comparisons were not performed because the sample size was too small.

Participant flow

Participant flow — Overall Study
MilestoneLeuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlacebo
Started1213
Completed64
Not completed69
Withdrew: Adverse event20
Withdrew: Disease progression25
Withdrew: Lost to follow-up02
Withdrew: Protocol violation02
Withdrew: Death10
Withdrew: Started chemotherapy10

Outcome measures

PrimaryMean Change From Baseline in IgM Response (Mcg/mL) Before Keyhole Limpet Hemocyanin (KLH) Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo

Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Serum immunoglobulin IgM antibodies were determined by enzyme-linked immunosorbent assay (ELISA). Baseline is defined as the IgM concentration before the KLH vaccination. Change from baseline was calculated as the IgM value postvaccination minus the IgM value at prevaccination.

Time frame:
Month 6 prevaccination (baseline) and Month 7 postvaccination
Reported as:
Mean · mcg/mL
Mean Change From Baseline in IgM Response (Mcg/mL) Before Keyhole Limpet Hemocyanin (KLH) Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo
mcg/mLLeuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlacebo
Mean IgM at baseline (mcg/mL)4.0 ± 3.83.0 ± 2.8
Mean IgM change from baseline (mcg/mL)2.91 ± 2.070.57 ± 0.83
SecondaryMean Change From Baseline in T Cell Excision Circles (TREC) Per 100,000 CD4+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant

CD4+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD4 cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD4+ cells minus pretransplant TREC /100,000 CD4+ cells.

Time frame:
Pretransplant and posttransplant (Month 12)
Reported as:
Mean · TREC /100,000 CD4+ cells
Mean Change From Baseline in T Cell Excision Circles (TREC) Per 100,000 CD4+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant
TREC /100,000 CD4+ cellsLeuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlacebo
Baseline TREC per 100,000 CD4+ cells67.524 ± 47.0863173.712 ± 206.1733
Mean change in TREC from baseline to final visit522.321 ± 920.790-63.950 ± 235.561
Statistical analysis
  • Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month vs Placebo · ANOVA · p = 0.125The statistical method used for a 1-way ANOVA between treatment groups.
SecondaryMean Change From Baseline in TREC Per 100,000 CD8+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant

CD8+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD8+ cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD8+ cells minus pretransplant TREC /100,000 CD8+ cells.

Time frame:
Pretransplant and posttransplant (Month 12)
Reported as:
Mean · TREC /100,000 CD8+ cells
Mean Change From Baseline in TREC Per 100,000 CD8+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant
TREC /100,000 CD8+ cellsLeuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlacebo
Baseline mean for TREC per 100,000 CD8+ cells181.673 ± 209.7599364.414 ± 280.3465
Mean change in TREC from baseline to final visit-10.811 ± 343.061-184.084 ± 282.405
Statistical analysis
  • Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month vs Placebo · ANOVA · p = 0.299The statistical method used for a 1-way ANOVA between treatment groups.
PrimaryMean Change From Baseline in IgG1 Response (Mcg/mL) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo

Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Serum immunoglobulin IgG1 antibodies were determined by enzyme-linked immunosorbent assay (ELISA). Baseline is defined as the IgG1 concentration before the KLH vaccination. Change from baseline was calculated as the IgG1 value postvaccination minus the IgG1 value at baseline.

Time frame:
Month 6 prevaccination (baseline) and Month 7 postvaccination
Reported as:
Mean · mcg/mL
Mean Change From Baseline in IgG1 Response (Mcg/mL) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo
mcg/mLLeuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlacebo
Mean IgG1 at baseline (mcg/mL)8.6 ± 9.110.8 ± 11.6
Mean IgG1 change from baseline (mcg/mL)46.16 ± 44.0116.76 ± 28.15
PrimaryMean Change From Baseline in Interferon Gamma Response (Spots/1 Million Cells) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo

Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo. Interferon gamma was determined by enzyme-linked immunosorbent spot-forming cell (ELISpot). Baseline is defined as the interferon gamma concentration obtained before the KLH vaccination. Change from baseline was calculated as the interferon gamma value postvaccination minus the interferon gamma value at baseline.

Time frame:
Month 6 prevaccination (baseline) and Month 7 postvaccination
Reported as:
Mean · spots/1 million cells
Mean Change From Baseline in Interferon Gamma Response (Spots/1 Million Cells) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo
spots/1 million cellsLeuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlacebo
Mean interferon gamma at baseline0.2 ± 3.2-1.4 ± 3.2
Mean interferon gamma change from baseline2.09 ± 4.8510.25 ± 11.41

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month—6/12 (50%)7/12 (58.3%)
Placebo—4/13 (30.8%)7/13 (53.8%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventLeuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlacebo
Febrile neutropeniaBlood and lymphatic system disorders1/121/13
PyrexiaGeneral disorders1/120/13
GastroenteritisInfections and infestations1/120/13
Pneumonia mycoplasmalInfections and infestations1/120/13
Respiratory tract infection bacterialInfections and infestations1/120/13
Respiratory failureRespiratory, thoracic and mediastinal disorders1/120/13
Deep vein thrombosisVascular disorders1/120/13
ThrombocytopeniaBlood and lymphatic system disorders0/121/13
PneumoniaInfections and infestations0/121/13
Respiratory tract infection viralInfections and infestations0/121/13
Most frequent other events
Showing 10 of 46
Most frequent other events
EventLeuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlacebo
PyrexiaGeneral disorders0/122/13
Back painMusculoskeletal and connective tissue disorders0/122/13
DyspneaRespiratory, thoracic and mediastinal disorders0/122/13
PalpitationsCardiac disorders1/120/13
HypogonadismEndocrine disorders1/120/13
Food poisoningGastrointestinal disorders1/120/13
Injection site swellingGeneral disorders1/120/13
Herpes zosterInfections and infestations1/120/13
Urinary tract infectionInfections and infestations1/120/13
Blood creatinine increasedInvestigations1/121/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Leuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlaceboTotal
<=18 years000
Between 18 and 65 years121325
>=65 years000
Age Continuous
Age Continuous(years)Leuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlaceboTotal
Mean49.0 ± 10.1647.4 ± 7.0448.2 ± 8.53
Sex: Female, Male
Sex: Female, Male(Participants)Leuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlaceboTotal
Female336
Male91019
Region of Enrollment
Region of Enrollment(participants)Leuprolide Acetate Depot (LAD) 11.25 mg 3 MonthPlaceboTotal
United States121325
08

Study locations

4 sites
  • Saint Louis, Missouri 63110, United States
  • New York, New York 10021, United States
  • Durham, North Carolina 27710, United States
  • Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006 and a primary completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2006
First posted
Jan 11, 2006
Start
Feb 2006
Primary completionActual
Feb 2009
Results first posted
May 6, 2010
Last update
May 6, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00275262
Lead sponsor
Abbott
Collaborators
Norwood Immunology Limited, M.D. Anderson Cancer Center, Dana-Farber Cancer Institute
First posted
Jan 11, 2006
Start date
Feb 2006
Primary completion
Feb 2009
Results posted
May 6, 2010
Last update
May 6, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion